Rahul Malhotra, MD
Interventional Cardiology · Glendale, AZNPI 1629079876
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Penumbra, Inc. at 25.1% of the total. Among interventional cardiology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 896 payments — averaging $91.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$20K
- Medtronic$19K
- Angiodynamics, Inc.$15K
- Boston Scientific$5K
- Veniti, Inc.$4K
- Amgen$2K
- plus $15K from 54 others
Across 13 payments — averaging $1746.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$14K
- EKOS Corporation$5K
- Cook Research Incorporated$3K
What the payments were for
- Consulting fees$4,2505%
- Speaking & faculty fees$6,4008%
- Travel & lodging$19,42324%
- Food & beverage$36,30144%
- Education$11,68814%
- Other$3,6004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$14,982
- EVLT$9,600
- Indigo$6,443
- Vici Venous Stent$4,250
- Auryon Atherectomy Catheter 1.5 mm OTW$3,600
- Auryon Atherectomy Catheter 2.0 mm OTW$3,600
- Auryon Atherectomy Catheter 0.9 mm OTW$3,600
- GENERAL - THERAPIES$2,049
- HawkOne$1,422
- Auryon Laser System 100-120 Vac$1,235
- ENDOCROSS Device$1,177
- Torus Stent Graft System$1,177
- VenaCure 1470 Pro$993
- Abre$925
- Micra$729
- Impella$617
- IN.PACT Admiral$580
- RESOLUTE ONYX$473
- SYMPLICITY G3$447
- TurboHawk$439
How this compares
$81,663 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 360 | $367,412 |
| EntrestoSacubitril/Valsartan | 192 | $185,015 |
| Repatha SureclickEvolocumab | 233 | $184,706 |
| XareltoRivaroxaban | 174 | $154,470 |
| BrilintaTicagrelor | 238 | $145,913 |
| FarxigaDapagliflozin Propanediol | 111 | $103,347 |
| VerquvoVericiguat | 53 | $49,918 |
| NexlizetBempedoic Acid/Ezetimibe | 32 | $19,404 |
| OzempicSemaglutide | 16 | $18,415 |
| Praluent PenAlirocumab | 28 | $18,299 |
| InpefaSotagliflozin | 18 | $13,743 |
| Ranolazine ErRanolazine | 104 | $12,914 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 27 | $12,529 |
| Rosuvastatin Calcium | 678 | $11,891 |
| Metoprolol Succinate | 708 | $10,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $543 | $367,412360 claims |
| AstraZenecaBrilinta, Farxiga | $679 | $249,260349 claims |
| NovartisEntresto | $966 | $185,015192 claims |
| Johnson & JohnsonXarelto | $223 | $154,470174 claims |
| MerckVerquvo | $584 | $49,91853 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $28 | $19,82239 claims |
| Esperion Therapeutics, Inc.Nexlizet | $20 | $19,40432 claims |
| Novo NordiskOzempic | $527 | $18,41516 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $102 | $13,74318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Glendale
- Anthony PozunGlendale$99K
- Paul SorajjaPhoenix$1.1M
- Hursh NaikAvondale$781K
- Thomas WaggonerTucson$617K
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
- Kapildeo LotunTucson$365K
- Azimuddin KhawajaPeoria$199K
- Rahul SharmaPeoria$195K
- Taral PatelScottsdale$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.